Slide 1: Interim Report Quarter 1, 2025
Interim Report Quarter 1, 2025 April 24, 2025
Slide 2: Magnus Groth, President and CEO
Magnus Groth President and CEO Every day our brands care for the hygiene and health of a billion people across 150 countries
Slide 3: Summary Q1
Summary Q1 Solid performance with higher sales and strong cash flow Organic Sales Growth EBITA excl IAC • All business areas contributing to sales growth +4.6% SEK • Higher prices and positive mix, stable volumes +2.1% Organic: 4,706m +3.8% • Strong growth in high-margin categories • Higher COGS and
Slide 4: New Share Buyback Program
New Share Buyback Program Allocation of Strong Operating Cash Flow • Essity B share buyback program of SEK 3bn • Begins April 24, 2025 and extends until AGM 2026 at the latest SEK • Safe Harbour compliant • Ambition to use as a recurring part of Essity’s capital allocation 3bn Interim Report Quarter
Slide 5: Product launches Q1 2025
Product launches Q1 2025 Interim Report Quarter 1, 2025 5
Slide 6: Product launches Q1 2025
Product launches Q1 2025 Interim Report Quarter 1, 2025 6
Slide 7: Product superiority: We keep raising the bar
Product superiority We keep raising the bar % of sales with superiority (product, brand, price) 71% 64% 59% 56% 40% 2017 2020 2023 2024 Q1 2025 7
Slide 8: Tariffs
Tariffs Interim Report Quarter 1, 2025 8
Slide 9: Net sales 2024 per region
Net sales 2024 per region Group’s ten largest markets, % of net sales USA, 14 % Germany, 12% UK, 8% Mexico, 8% France, 8% Spain, 6% Netherlands, 4% Colombia, 3% North America Europe Italy, 3% 17% 60% Canada, 3% Other, 31% Latin America Other Asia 17% 4% 2%
Slide 10: Essity's manufacturing footprint
Essity’s manufacturing footprint Professional Medical Hygiene Solutions Personal Australasia Care Consumer Contract Tissue Manufacturer
Slide 11: North America
North America • Professional Hygiene – >90% produced domestically in US – Imports to Canada from US • Incontinence Products Health Care and Retail – Production both in US and Canada with flows in between • Medical Solutions – Some imports to US from Mexico TISSUE PROFESSIONAL PERSONAL MEDICAL CONSUM
Slide 12: Conclusion
Conclusion • A majority of Essity’s products are locally manufactured • More than 80% of our US sales is produced in the US with material mainly sourced within US • Imports/exports between US and China are limited • A majority of the flows between US/Canada/Mexico are exempt or under USMCA agreement
Slide 13: Fredrik Rystedt, EVP and CFO
Fredrik Rystedt EVP and CFO Every day our brands care for the hygiene and health of a billion people across 150 countries
Slide 14: Three attractive business areas
Three attractive business areas Health & Medical Health & Professional Incontinence Products 20% Medical Hygiene Health Care 25% 12% Medical Solutions 8% Net sales Q1 2025 Consumer Goods Consumer Baby Care Goods 5% 55% Incontinence Consumer Products Tissue Retail 32% 8% Feminine Care 10% Professiona
Slide 15: Health & Medical
Health & Medical Q1 2025 vs Q1 2024 Organic sales growth +1.7% • Volume +1.3% • Price/mix +0.4% • Incontinence Products Health Care -0.1% • Medical Solutions +4.2% Profitability • EBITA excl. IAC SEK 1,231m, -5% • EBITA margin excl. IAC 17.7%, -120bps 15
Slide 16: Consumer Goods
Consumer Goods Q1 2025 vs Q1 2024 Organic sales growth +2.9% • Volume +1.2% • Price/Mix +1.7% • Incontinence Products Retail +6.9% • Feminine Care +5.1 • Baby Care -6.5% • Consumer Tissue +2.7% Profitability • EBITA excl. IAC SEK 2,443m, -4% • EBITA margin excl. IAC 12.7%, -50bps 16
Slide 17: Professional Hygiene
Professional Hygiene Q1 2025 vs Q1 2024 Organic sales growth +0.7% • Volume -3.6% • Higher prices and positive mix +4.3% Profitability • EBITA excl. IAC SEK 1,413m, +6% • EBITA margin excl. IAC 16.1%, +80bps 17
Slide 18: Higher sales prices and positive mix
Higher sales prices and positive mix +2.1% -1.7% 34.9 0.0% 35.0 Net sales Volume Price/mix Currency Net sales Q1 2024 Q1 2025 (SEKbn) Organic sales growth: +2.1% (SEKbn) Reported growth: +0.4% Interim Report Quarter 1, 2025 18
Slide 19: EBITA margin excl. IAC
EBITA margin excl. IAC 14.0% -40bps +40bps -50bps 13.5% - Higher COGS + Higher sales prices + Growth in high-margin categories Q1 2024 Impact Gross A&P SG&A Q1 2025 Profit Margin (excl. A&P) Interim Report Quarter 1, 2025 19
Slide 20: Strong cash flow generation
Strong cash flow generation Operating Cash flow SEKbn 6.5 6.1 5.9 4.3 3.8 3.2 3.3 2.9 2.8 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Interim Report Quarter 1, 2025 20
Slide 21: Strengthened balance sheet
Strengthened balance sheet SEKbn 70 5 62.9 4.5 60 54.4 55.4 53.7 52.5 50.9 4 50 3.5 42.7 3 40 3.0 3.1 2.8 30.8 2.5 30 2.8 26.8 2 2.3 20 2.0 1.5 1.8 1 10 1.2 1.0 0.5 0 0 2017 2018 2019 2020 2021 2022 2023 2024 3M 2025 Net Debt, SEKbn Net Debt / EBITDA excl. IAC Interim Report Quarter 1, 2025 21
Slide 22: Magnus Groth, President and CEO
Magnus Groth President and CEO Every day our brands care for the hygiene and health of a billion people across 150 countries
Slide 23: Summary
Summary • A solid Q1 with positive sales growth in all business areas, stable profitability and strong cash flow • Strong growth platform with leading market positions • Efficient supply chain with manufacturing close to customers and consumers • Uncertainty remains regarding global macro economy an
Slide 24: Forward-looking statements
This presentation may contain forward-looking statements. Such statements are based on our current expectations and are subject to certain risks and uncertainties that could negatively affect our business. Please read our most recent annual report for a better understanding of these risks and uncert
Slide 25: Q&A
Q&A Interim Report Quarter 1, 2025 25
Slide 26: essity
essity